A 27-year-old man with chronic hepatitis C infection presents with elevated liver enzyme levels. A liver biopsy reveals mild hepatic fibrosis.
His laboratory results are as follows:
Test | Result | Normal Range |
|---|---|---|
ALT | 75 IU/L | [5–40 IU/L] |
AST | 55 IU/L | [12–40 IU/L] |
Which of the following medications should be avoided in this patient due to its potential for hepatotoxicity?
A. Amoxicillin
B. Pregabalin
C. Cephalexin
D. Methotrexate
D. Methotrexate
Methotrexate is well-known for dose-dependent hepatotoxicity (including steatosis, fibrosis, and cirrhosis) and requires regular liver enzyme monitoring. It is generally avoided or used with extreme caution in patients who already have chronic liver disease (such as hepatitis C with elevated transaminases and biopsy-proven fibrosis), as the risk of progressive hepatic injury is substantially increased.
The other agents are far less concerning in this setting:
Amoxicillin and cephalexin can rarely cause idiosyncratic cholestatic or mixed hepatitis, but this is uncommon and not a reason for routine avoidance in mild chronic hepatitis C.
Pregabalin has minimal hepatic metabolism and only rare reports of liver injury.
Thus methotrexate is the clear choice to avoid.
Exam Pearl: Methotrexate can cause hepatic fibrosis. Exercise particular caution in patients with pre-existing liver disease, chronic viral hepatitis, or abnormal liver function tests.
Clinical note: The decision to use methotrexate requires individual assessment; chronic hepatitis C is not automatically an absolute contraindication in every patient.
A 65-year-old man with diabetes mellitus is admitted to the Emergency Department (ED) with a 3-day history of productive cough, shortness of breath, and chest pain. Chest X-ray reveals bilateral lower-lobe infiltrates, consistent with pneumonia. A nasal swab confirms infection with the influenza A (H1N1) virus.
Which of the following antiviral medications is the drug of choice for treating this infection?
A. Ribavirin
B. Acyclovir
C. Oseltamivir
D. Ganciclovir
C. Oseltamivir
Oseltamivir (a neuraminidase inhibitor) is the preferred antiviral for influenza A (including H1N1) and influenza B. It is recommended for high-risk patients (age ≥65 years, diabetes, or evidence of lower-respiratory-tract involvement) and is most effective when started early, though it can still be beneficial later in severe or complicated illness.
The other agents are not appropriate:
Acyclovir is active against herpesviruses (HSV, VZV).
Ganciclovir is used primarily for cytomegalovirus.
Ribavirin has activity against certain RNA viruses (e.g., RSV, hepatitis C) but is not a standard or preferred therapy for influenza.
Exam Pearl: Oseltamivir is the preferred antiviral for hospitalized patients with influenza, even when treatment begins more than 48 hours after symptom onset.
Which of the following is the recommended first-line treatment for uncomplicated malaria caused by Plasmodium falciparum in Saudi Arabia?
A. Quinine
B. Primaquine
C. Artesunate
D. Doxycycline
C. Artesunate
In Saudi Arabia, artemisinin-based combination therapies (ACTs) are the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria. Older national guidelines (e.g., Ministry of Health policies around 2016–2019) specifically listed artesunate + sulfadoxine-pyrimethamine (AS + SP) as first-line (with artesunate + mefloquine as an alternative), and artemether-lumefantrine as second-line. More recent guidance (Saudi National Guideline for Malaria Management, 4th edition, 2022) shifted the preferred first-line to artemether-lumefantrine, but artesunate remains a core component of recommended ACTs and is still widely referenced in local practice and documents for falciparum malaria.
The other options are not appropriate as first-line monotherapy or primary therapy for uncomplicated P. falciparum:
Quinine is typically reserved as a later-line or alternative regimen (often combined with doxycycline).
Primaquine is used primarily for its gametocytocidal effect (single low dose added to ACT) or for radical cure of P. vivax/P. ovale, not as the main blood-stage treatment for falciparum.
Doxycycline is mainly used in combination (e.g., with quinine as a later option) or for prophylaxis, not as standalone first-line therapy.
Thus, among the listed choices, artesunate is the correct selection.
Important Exam Pearl
- Uncomplicated P. falciparum: Artemether/lumefantrine (current Saudi guideline).
- Severe P. falciparum: Intravenous artesunate.
- P. vivax: Chloroquine plus primaquine, where appropriate.
A 57-year-old man presents to an urgent care clinic with a 2-day history of high fever, generalized muscle and bone aches, headache, and loss of appetite. He was previously in good health and reports recent close contact with a friend diagnosed with influenza.
Which of the following is the most appropriate management?
A. Amoxicillin 500 mg orally every 8 hours for 10 days
B. Azithromycin 500 mg orally once daily for 3 days
C. Amoxicillin/clavulanic acid 1 g orally every 12 hours for 7 days
D. Supportive treatment (e.g., fluids, rest, antihistamines, and paracetamol)
D. Supportive treatment (e.g., fluids, rest, antihistamines, and paracetamol)
The presentation (acute high fever, myalgias/arthralgias, headache, anorexia) plus recent close contact with a confirmed influenza case is classic for uncomplicated influenza. In an otherwise healthy adult without high-risk features (e.g., age ≥65 years, chronic illness, pregnancy, or immunosuppression), management is supportive: rest, hydration, and symptomatic relief with analgesics/antipyretics.
Antibiotics (amoxicillin, azithromycin, or amoxicillin/clavulanate) have no role in pure viral influenza and are not indicated in the absence of evidence of secondary bacterial infection. Antiviral therapy (e.g., oseltamivir) may be considered in selected high-risk or severely ill patients if started early, but it is not listed among the options and is not required as first-line management in this uncomplicated case.
Which of the following beta-blockers has proven mortality benefits and is recommended for the treatment of patients with heart failure with reduced ejection fraction (HFrEF)?
A. Esmolol
B. Atenolol
C. Labetalol
D. Carvedilol
D. Carvedilol
Carvedilol is one of the three evidence-based beta-blockers (along with bisoprolol and metoprolol succinate) proven in large randomized trials (e.g., COPERNICUS) to reduce mortality and hospitalizations in patients with HFrEF. Guidelines (ACC/AHA, ESC) specifically recommend these agents for all patients with HFrEF unless contraindicated.
It blocks:
- β1 receptors: Reduces heart rate and myocardial oxygen demand.
- β2 receptors: Blocks beta-2 adrenergic activity.
- α1 receptors: Causes vasodilation and reduces peripheral vascular resistance.
Carvedilol improves cardiac function and reduces mortality and hospitalization in patients with HFrEF.
The other options lack this evidence and are not guideline-recommended for chronic HFrEF:
Esmolol is an ultra-short-acting IV agent used only for acute rate control.
Atenolol has no proven mortality benefit in HFrEF and is not preferred.
Labetalol is primarily used for hypertension (including hypertensive emergencies or pregnancy) and is not indicated for HFrEF.
Remember: Not all beta-blockers are interchangeable in heart failure. Use beta-blockers with proven clinical outcome benefits.
----
Disclaimer: This blog post is intended solely for educational and examination-preparation purposes. The clinical cases, multiple-choice questions, answers, and explanations are provided to support pharmacy students and healthcare professionals preparing for licensing and board examinations, including NAPLEX, DHA, MOH, HAAD, SPLE, and other pharmacy examinations.
The information presented should not be considered a substitute for professional medical advice, clinical judgment, or current evidence-based treatment guidelines. Treatment recommendations may vary depending on patient characteristics, local protocols, antimicrobial resistance patterns, and updated clinical guidelines.
Always consult current official guidelines and qualified healthcare professionals before making clinical decisions. The authors accept no responsibility for decisions made solely on the basis of this educational content.
0 Comments